Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H34O5 |
| Molecular Weight | 390.5131 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC[C@@H](O)\C=C\C1=C(/C=C/[C@@H](O)[C@@H](O)CCCC(=O)OC)C=CC=C1
InChI
InChIKey=CHUQDPKHYXGMEB-IQOAYPBESA-N
InChI=1S/C23H34O5/c1-3-4-5-11-20(24)16-14-18-9-6-7-10-19(18)15-17-22(26)21(25)12-8-13-23(27)28-2/h6-7,9-10,14-17,20-22,24-26H,3-5,8,11-13H2,1-2H3/b16-14+,17-15+/t20-,21+,22-/m1/s1
Benzo-lipoxin A4 as a bLXA4-ME also known as ClinRinse-1 participated in phase II clinical trials for the treatment of gingival diseases. It was shown that nano-proresolving medicines (NPRM) containing a lipoxin analog (benzo-lipoxin A4, bLXA4) was a mimetic of endogenous resolving mechanisms with potent bioactions. That offered a new therapeutic tissue-engineering approach for the treatment of chronic osteolytic inflammatory diseases.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
362516-29-8
Created by
admin on Mon Mar 31 22:07:28 GMT 2025 , Edited by admin on Mon Mar 31 22:07:28 GMT 2025
|
PRIMARY | |||
|
KA6Q1QB6DB
Created by
admin on Mon Mar 31 22:07:28 GMT 2025 , Edited by admin on Mon Mar 31 22:07:28 GMT 2025
|
PRIMARY | |||
|
10222011
Created by
admin on Mon Mar 31 22:07:28 GMT 2025 , Edited by admin on Mon Mar 31 22:07:28 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
